In ER+ BC, CDK4/6is are usually utilized in combination with ERis—studies of acquired clinical resistance to the combination found that acquired alterations in RB1, CCND1, CDK4/6, CCNE1/2, and AURKA were enriched in resistant tumors (53, 79). Here, CDK4 is linked to breast cancer.